These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21118368)

  • 1. Adverse events in therapeutic apheresis: a single center survey of various therapies.
    Ishihara T; Inoue S; Takagi Y; Shimomura T; Sagami Y; Katayama S; Eguchi Y; Watase K; Miyamoto M; Minakata T
    Ther Apher Dial; 2010 Dec; 14(6):589-95. PubMed ID: 21118368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic apheresis: results from a single center in Turkey.
    Yavasoglu I; Kadikoylu G; Akyol A; Bolaman Z
    Transfus Apher Sci; 2007 Jun; 36(3):249-53. PubMed ID: 17556022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic apheresis in Sweden: update of epidemiology and adverse events.
    Norda R; Stegmayr BG;
    Transfus Apher Sci; 2003 Oct; 29(2):159-66. PubMed ID: 12941356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WAA apheresis registry in the Czech Republic: two centers experience.
    Bláha M; Pták J; Cáp J; Ceeová V; Masín V; Filip S; Blazek M
    Transfus Apher Sci; 2009 Aug; 41(1):27-31. PubMed ID: 19524488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. World apheresis registry report.
    Stegmayr B; Ptak J; Wikström B
    Transfus Apher Sci; 2007 Feb; 36(1):13-6. PubMed ID: 17234456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Italian Registry of Pediatric Therapeutic Apheresis: a report on activity during 2005.
    De Silvestro G; Tison T; Vicarioto M; Bagatella P; Stefanutti C; Marson P
    J Clin Apher; 2009; 24(1):1-5. PubMed ID: 19073013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden.
    Dittrich-Riediger J; Schatz U; Hohenstein B; Julius U
    Atheroscler Suppl; 2015 May; 18():45-52. PubMed ID: 25936304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing (yin-yang) hypothesis for assessment of effective apheresis therapies.
    Nosé Y
    Ther Apher; 1999 Nov; 3(4):280-6. PubMed ID: 10608718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One year experience with a low density lipoprotein apheresis system.
    Durst R; Rund D; Schurr D; Eliav O; Ben-Yehuda D; Shpizen S; Ben-Avi L; Schaap T; Pelz I; Leitersdorf E
    Isr Med Assoc J; 2002 Sep; 4(9):677-80. PubMed ID: 12440228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for acute, moderate to severe donor reactions associated with multicomponent apheresis collections.
    Yuan S; Gornbein J; Smeltzer B; Ziman AF; Lu Q; Goldfinger D
    Transfusion; 2008 Jun; 48(6):1213-9. PubMed ID: 18346014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National survey of apheresis activity in Italy (2000).
    De Silvestro G; Marson P; Russo GE; Vicarioto M; Donadel C
    Transfus Apher Sci; 2004 Feb; 30(1):61-71. PubMed ID: 14746823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical considerations for planning a therapeutic apheresis procedure.
    Shelat SG
    Am J Med; 2010 Sep; 123(9):777-84. PubMed ID: 20541168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of immediate adverse effects associated with therapeutic apheresis.
    McLeod BC; Sniecinski I; Ciavarella D; Owen H; Price TH; Randels MJ; Smith JW
    Transfusion; 1999 Mar; 39(3):282-8. PubMed ID: 10204591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of DALI LDL-apheresis at high blood flow rates: a prospective multicenter study.
    Wendler T; Schilling R; Lennertz A; Sodemann K; Kleophas W; Messner H; Riechers G; Wagner J; Keller C; Bosch T
    J Clin Apher; 2003; 18(4):157-66. PubMed ID: 14699591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moderate and severe adverse events associated with apheresis donations: incidences and risk factors.
    Yuan S; Ziman A; Smeltzer B; Lu Q; Goldfinger D
    Transfusion; 2010 Feb; 50(2):478-86. PubMed ID: 19843285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks.
    Stefanutti C; Lanti A; Di Giacomo S; Mareri M; De Lorenzo F; Landolfo A; Isacchi G
    Transfus Apher Sci; 2004 Aug; 31(1):3-10. PubMed ID: 15294188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey of therapeutic hemapheresis in Norway year 2000.
    Taraldsrud E; Kvalheim G; Jørstad S; Stavem K; Aandahl GS
    Transfus Apher Sci; 2003 Apr; 28(2):135-41. PubMed ID: 12679117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic apheresis: a review of complications and recommendations for prevention and management.
    Mokrzycki MH; Balogun RA
    J Clin Apher; 2011; 26(5):243-8. PubMed ID: 21898573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The technique of therapeutic apheresis. Removal of abnormal blood elements may succeed when all else fails.
    McLeod BC
    J Crit Illn; 1991 May; 6(5):487-95. PubMed ID: 10147917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks of leukapheresis and how to manage them-A non-systematic review.
    Stenzinger M; Bonig H
    Transfus Apher Sci; 2018 Oct; 57(5):628-634. PubMed ID: 30287071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.